The biopharmaceutical company appointed Michael A. Sherman, former CEO of Endocyte Inc., as CEO. It also appointed Michael T. Andriole, former chief financial officer of Endocyte Inc., to the newly created position of chief business officer.
Read More
ContraVir Pharmaceuticals Inc., a pharmaceutical company headquartered in New Jersey, decided to terminate the license agreement between ContraVir and Chimerix dated Dec. 17, 2014. The termination of the agreement will be effective on June 1.
Read More
Durham-based Chimerix Inc. disclosed Wednesday that former CEO Michelle Berrey will collect severance benefits in the form of receiving her base salary 18 months following her departure.
Read More
Chimerix CEO and President Michelle Berrey has resigned, effective immediately, according to a release Wednesday morning.
Read More
Kenneth Moch, a former CEO of Chimerix, has retracted allegations made against Pappas Ventures and also agreed to pay a settlement in a case dating back to October 2014.
Read More
Chimerix, a Durham-based biopharmaceutical company that’s developing novel antiviral medicines for unmet medical needs,, is reporting progress on two fronts.
Read MoreChimerix names a new chair of its board, and also appoints three new board members.
Read MoreBiopharmaceutical company Chimerix Inc. will give raises to four executive officers, including its CEO and chief medical officer, for 2018, along with bonuses for the previous year’s performance.
Read More
